

Supplemental Information: Online Resource 2 – Supplemental Results

European Journal of Clinical Pharmacology

Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study

Vladimir Trkulja, Ivan Kodvanj

Corresponding author: Vladimir Trkulja, MD, PhD
Department of Pharmacology
Zagreb University School of Medicine
Šalata 11, 10000 Zagreb, CROATIA
Fax: +385-1-49-200-49
Phone: +385-98-325-307
E-mail: vladimir.trkulja@mef.hr

Contents

Table S5. Study 1: Matching covariates in Cohort A and Cohort B before and after matching

Table A6. Study 1: Matching covariates in Cohort A and Cohort C before and after matching

Table S7. Study 1: Matching covariates in Cohort B and Cohort C before and after matching

Table S8. Study 2: Matching covariates in Cohort Fluvoxamine and Cohort Paroxetine before and after matching

Table S5 Study 1: Matching covariates in Cohort A and Cohort B before [count (%)] and after matching [weighted count (%)] with standardized differences (d).

| Characteristics | Before matching | | | After matching | | |
|--------------------------------|-----------------|--------------|--------|----------------|-----------------|-------|
| | Cohort A | Cohort B | d | Cohort A | Cohort B | d |
| n | 1016 | 95984 | | 749 | 31336 | |
| Age | | | | | | |
| [16,21) | 36 (3.5) | 1389 (1.4) | 0.135 | 17.5 (2.3) | 733.5 (2.3) | 0.000 |
| [21,26) | 31 (3.1) | 2142 (2.2) | 0.051 | 27.7 (3.7) | 1160.3 (3.7) | 0.000 |
| [26,31) | 45 (4.4) | 2869 (3.0) | 0.076 | 41.6 (5.5) | 1738.4 (5.5) | 0.000 |
| [31,36) | 51 (5.0) | 4034 (4.2) | 0.039 | 57.8 (7.7) | 2418.2 (7.7) | 0.000 |
| [36,41) | 85 (8.4) | 6002 (6.3) | 0.081 | 85.7 (11.4) | 3585.3 (11.4) | 0.000 |
| [41,46) | 83 (8.2) | 7706 (8.0) | 0.005 | 98.5 (13.1) | 4120.5 (13.1) | 0.000 |
| [46,51) | 96 (9.4) | 9166 (9.5) | -0.003 | 119.1 (15.9) | 4980.9 (15.9) | 0.000 |
| [51,56) | 106 (10.4) | 10689 (11.1) | -0.023 | 115.9 (15.5) | 4850.1 (15.5) | 0.000 |
| [56,61) | 111 (10.9) | 11457 (11.9) | -0.032 | 88.9 (11.9) | 3720.1 (11.9) | 0.000 |
| [61,66) | 90 (8.9) | 10697 (11.1) | -0.076 | 56.0 (7.5) | 2345.0 (7.5) | 0.000 |
| [66,71) | 68 (6.7) | 8561 (8.9) | -0.083 | 17.0 (2.3) | 713.0 (2.3) | 0.000 |
| [71,76) | 73 (7.2) | 6715 (7.0) | 0.007 | 12.5 (1.7) | 521.5 (1.7) | 0.000 |
| [76,81) | 45 (4.4) | 5466 (5.7) | -0.058 | 3.7 (0.5) | 153.3 (0.5) | 0.000 |
| [81,86) | 55 (5.4) | 4924 (5.1) | 0.013 | 5.6 (0.8) | 236.4 (0.8) | 0.000 |
| [86,91) | 35 (3.4) | 2984 (3.1) | 0.019 | 1.3 (0.2) | 55.7 (0.2) | 0.000 |
| [91,96) | 5 (0.5) | 1011 (1.1) | -0.064 | 0.1 (0.0) | 3.9 (0.0) | 0.000 |
| [96,101) | 1 (0.1) | 166 (0.2) | -0.020 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| [101,106) | 0 (0.0) | 6 (0.0) | -0.011 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| [106,111) | 0 (0.0) | 0 (0.0) | 0.000 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Sex | | | | | | |
| Male | 441 (43.4) | 33604 (35.0) | 0.173 | 221.0 (29.5) | 9245.0 (29.5) | 0.000 |
| Female | 575 (56.6) | 62380 (65.0) | -0.173 | 528.0 (70.5) | 22091.0 (70.5) | 0.000 |
| Vaccination status | | | | | | |
| 1/1, >90 days | 0 (0.0) | 1 (0.0) | -0.005 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/1, <14 days | 0 (0.0) | 13 (0.0) | -0.016 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/1, 14-90 days | 0 (0.0) | 8 (0.0) | -0.013 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Not vaccinated | 958 (94.3) | 90719 (94.5) | -0.010 | 747.6 (99.8) | 31275.4 (99.8) | 0.000 |
| 1/2, >90 days | 0 (0.0) | 28 (0.0) | -0.024 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/2, <14 days | 23 (2.3) | 1724 (1.8) | 0.033 | 0.4 (0.0) | 15.6 (0.0) | 0.000 |
| 1/2, 14-90 days | 27 (2.7) | 2431 (2.5) | 0.008 | 1.0 (0.1) | 41.0 (0.1) | 0.000 |
| 2/2, >90 days | 1 (0.1) | 237 (0.2) | -0.036 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 2/2, <14 days | 0 (0.0) | 298 (0.3) | -0.079 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 2/2, 14-90 days | 7 (0.7) | 525 (0.5) | 0.018 | 0.1 (0.0) | 3.9 (0.0) | 0.000 |
| Period | | | | | | |
| Up to January 9, 2021 | 591 (58.2) | 55623 (58.0) | 0.004 | 456.8 (61.0) | 19109.2 (61.0) | 0.000 |
| January 10 to July 15, 2021 | 408 (40.2) | 39112 (40.7) | -0.012 | 290.4 (38.8) | 12147.6 (38.8) | 0.000 |
| After July 15, 2021 | 17 (1.7) | 1249 (1.3) | 0.031 | 1.9 (0.3) | 79.1 (0.3) | 0.000 |
| CCI | | | | | | |
| 0 | 609 (59.9) | 55122 (57.4) | 0.051 | 706.0 (94.3) | 29538.0 (94.3) | 0.000 |
| 1-2 | 293 (28.8) | 31229 (32.5) | -0.080 | 42.5 (5.7) | 1776.5 (5.7) | 0.000 |
| 3-4 | 86 (8.5) | 7375 (7.7) | 0.029 | 0.5 (0.1) | 21.5 (0.1) | 0.000 |
| >=5 | 28 (2.8) | 2258 (2.4) | 0.026 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Comorbidities | | | | | | |
| Atrial fibrillation/undulation | 61 (6.0) | 5850 (6.1) | -0.004 | 1.1 (0.1) | 44.9 (0.1) | 0.000 |
| Autoimmune disease | 112 (11.0) | 13295 (13.9) | -0.086 | 17.5 (2.3) | 732.5 (2.3) | 0.000 |
| Cancer | 58 (5.7) | 7569 (7.9) | -0.087 | 2.6 (0.4) | 110.4 (0.4) | 0.000 |
| Congestive heart failure | 30 (3.0) | 3907 (4.1) | -0.061 | 0.3 (0.0) | 10.7 (0.0) | 0.000 |
| COPD | 112 (11.0) | 12808 (13.3) | -0.071 | 18.5 (2.5) | 775.5 (2.5) | 0.000 |
| IHD or CVD | 149 (14.7) | 12803 (13.3) | 0.038 | 6.4 (0.9) | 268.6 (0.9) | 0.000 |
| Renal disease | 23 (2.3) | 2067 (2.2) | 0.008 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Diabetes + complications | 19 (1.9) | 1611 (1.7) | 0.015 | 0.0 (0.0) | 2.0 (0.0) | 0.000 |
| Diabetes w/o complications | 165 (16.2) | 15155 (15.8) | 0.012 | 13.0 (1.7) | 544.0 (1.7) | 0.000 |
| Dementia | 37 (3.6) | 2356 (2.5) | 0.069 | 0.5 (0.1) | 21.5 (0.1) | 0.000 |
| Immunocompromised | 14 (1.4) | 1559 (1.6) | -0.020 | 0.1 (0.0) | 2.9 (0.0) | 0.000 |
| RAAS inhibitors | 293 (28.8) | 30443 (31.7) | -0.063 | 88.0 (11.8) | 3682.0 (11.8) | 0.000 |
| Diuretics | 125 (12.3) | 14193 (14.8) | -0.073 | 7.2 (1.0) | 300.8 (1.0) | 0.000 |
| F10-F19 | 28 (2.8) | 2650 (2.8) | 0.000 | 1.1 (0.1) | 43.9 (0.1) | 0.000 |
| F20-F29 | 119 (11.7) | 5306 (5.5) | 0.222 | 18.7 (2.5) | 780.3 (2.5) | 0.000 |
| F30-F39 | 446 (43.9) | 20856 (21.7) | 0.486 | 121.7 (16.3) | 5092.3 (16.3) | 0.000 |

| | | | | | | |
|---|------------|--------------|--------|---------------|-----------------|--------|
| F40-F48 | 692 (68.1) | 71242 (74.2) | -0.135 | 655.1 (87.5) | 27408.9 (87.5) | 0.000 |
| Any of F04-F09, F50-F59, F60-F69, F70-F79, F80-F89, F90-F98 | 229 (22.5) | 19431 (20.2) | 0.056 | 47.6 (6.4) | 1992.4 (6.4) | 0.000 |
| COVID-related hospitalization | 34 (3.3) | 3128 (3.3) | 0.019 | 5.3 (0.7) | 160.7 (0.5) | 0.024 |
| All-cause 30-day hospitalization | 127 (12.5) | 11266 (11.7) | 0.023 | 62.1 (8.3) | 1378.7 (4.4) | 0.119 |
| COVID-related death | 38 (3.7) | 4261 (4.4) | -0.035 | 2.8 (0.4) | 161.8 (0.5) | -0.007 |

Table S6 Study 1: Matching covariates in Cohort A and Cohort C before [count (%)] and after matching [weighted count (%)] with standardized differences (d).

| Characteristics | Before matching | | | After matching | | |
|----------------------------------|-----------------|----------------|--------|----------------|------------------|-------|
| | Cohort A | Cohort C | d | Cohort A | Cohort C | d |
| n | 1016 | 275804 | | 866 | 222792 | |
| Age | | | | | | |
| [16,21) | 36 (3.5) | 21127 (7.7) | -0.180 | 73.7 (8.5) | 18966.3 (8.5) | 0.000 |
| [21,26) | 31 (3.1) | 26298 (9.5) | -0.269 | 92.9 (10.7) | 23895.1 (10.7) | 0.000 |
| [26,31) | 45 (4.4) | 29134 (10.6) | -0.235 | 102.0 (11.8) | 26237.0 (11.8) | 0.000 |
| [31,36) | 51 (5.0) | 30974 (11.2) | -0.229 | 107.4 (12.4) | 27640.6 (12.4) | 0.000 |
| [36,41) | 85 (8.4) | 32123 (11.6) | -0.109 | 114.0 (13.2) | 29325.0 (13.2) | 0.000 |
| [41,46) | 83 (8.2) | 29678 (10.8) | -0.089 | 102.1 (11.8) | 26259.9 (11.8) | 0.000 |
| [46,51) | 96 (9.4) | 24825 (9.0) | 0.015 | 81.5 (9.4) | 20961.5 (9.4) | 0.000 |
| [51,56) | 106 (10.4) | 22057 (8.0) | 0.084 | 70.2 (8.1) | 18058.8 (8.1) | 0.000 |
| [56,61) | 111 (10.9) | 19061 (6.9) | 0.141 | 54.6 (6.3) | 14040.4 (6.3) | 0.000 |
| [61,66) | 90 (8.9) | 14962 (5.4) | 0.134 | 35.5 (4.1) | 9121.5 (4.1) | 0.000 |
| [66,71) | 68 (6.7) | 10422 (3.8) | 0.131 | 17.3 (2.0) | 4454.7 (2.0) | 0.000 |
| [71,76) | 73 (7.2) | 6473 (2.3) | 0.229 | 9.3 (1.1) | 2398.7 (1.1) | 0.000 |
| [76,81) | 45 (4.4) | 4138 (1.5) | 0.173 | 2.4 (0.3) | 611.6 (0.3) | 0.000 |
| [81,86) | 55 (5.4) | 2820 (1.0) | 0.251 | 2.5 (0.3) | 646.5 (0.3) | 0.000 |
| [86,91) | 35 (3.4) | 1274 (0.5) | 0.217 | 0.6 (0.1) | 166.4 (0.1) | 0.000 |
| [91,96) | 5 (0.5) | 362 (0.1) | 0.065 | 0.0 (0.0) | 8.0 (0.0) | 0.000 |
| [96,101) | 1 (0.1) | 75 (0.0) | 0.028 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| [101,106) | 0 (0.0) | 0 (0.0) | 0.000 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| [106,111) | 0 (0.0) | 1 (0.0) | -0.003 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Sex | | | | | | |
| Male | 441 (43.4) | 144548 (52.4) | -0.181 | 434.8 (50.2) | 111856.2 (50.2) | 0.000 |
| Female | 575 (56.6) | 131256 (47.6) | 0.181 | 431.2 (49.8) | 110935.8 (49.8) | 0.000 |
| Vaccination status | | | | | | |
| 1/1, >90 days | 0 (0.0) | 1 (0.0) | -0.003 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/1, <14 days | 0 (0.0) | 38 (0.0) | -0.017 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/1, 14-90 days | 0 (0.0) | 43 (0.0) | -0.018 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Not vaccinated | 958 (94.3) | 269392 (97.7) | -0.173 | 864.1 (99.8) | 222315.9 (99.8) | 0.000 |
| 1/2, >90 days | 0 (0.0) | 16 (0.0) | -0.011 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/2, <14 days | 23 (2.3) | 2667 (1.0) | 0.103 | 0.8 (0.1) | 207.2 (0.1) | 0.000 |
| 1/2, 14-90 days | 27 (2.7) | 2645 (1.0) | 0.128 | 1.0 (0.1) | 253.0 (0.1) | 0.000 |
| 2/2, >90 days | 1 (0.1) | 201 (0.1) | 0.009 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 2/2, <14 days | 0 (0.0) | 205 (0.1) | -0.039 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 2/2, 14-90 days | 7 (0.7) | 596 (0.2) | 0.070 | 0.1 (0.0) | 15.9 (0.0) | 0.000 |
| Period | | | | | | |
| Up to January 9, 2021 | 591 (58.2) | 163836 (59.4) | -0.025 | 535.9 (61.9) | 137861.1 (61.9) | 0.000 |
| January 10 to July 15, 2021 | 408 (40.2) | 106379 (38.6) | 0.032 | 324.0 (37.4) | 83354.0 (37.4) | 0.000 |
| After July 15, 2021 | 17 (1.7) | 5589 (2.0) | -0.026 | 6.1 (0.7) | 1576.9 (0.7) | 0.000 |
| CCI | | | | | | |
| 0 | 609 (59.9) | 230007 (83.4) | -0.539 | 819.6 (94.6) | 210856.4 (94.6) | 0.000 |
| 1-2 | 293 (28.8) | 40370 (14.6) | 0.350 | 45.9 (5.3) | 11804.1 (5.3) | 0.000 |
| 3-4 | 86 (8.5) | 4380 (1.6) | 0.319 | 0.5 (0.1) | 127.5 (0.1) | 0.000 |
| >=5 | 28 (2.8) | 1047 (0.4) | 0.192 | 0.0 (0.0) | 4.0 (0.0) | 0.000 |
| Comorbidities | | | | | | |
| Atrial fibrillation/undulation | 61 (6.0) | 4017 (1.5) | 0.242 | 0.7 (0.1) | 190.3 (0.1) | 0.000 |
| Autoimmune disease | 112 (11.0) | 14281 (5.2) | 0.215 | 20.8 (2.4) | 5361.2 (2.4) | 0.000 |
| Cancer | 58 (5.7) | 7109 (2.6) | 0.158 | 2.7 (0.3) | 686.3 (0.3) | 0.000 |
| Congestive heart failure | 30 (3.0) | 2149 (0.8) | 0.161 | 0.1 (0.0) | 16.9 (0.0) | 0.000 |
| COPD | 112 (11.0) | 17171 (6.2) | 0.172 | 22.8 (2.6) | 5872.2 (2.6) | 0.000 |
| IHD or CVD | 149 (14.7) | 8240 (3.0) | 0.421 | 3.5 (0.4) | 912.5 (0.4) | 0.000 |
| Renal disease | 23 (2.3) | 1334 (0.5) | 0.153 | 0.0 (0.0) | 6.0 (0.0) | 0.000 |
| Diabetes + complications | 19 (1.9) | 1131 (0.4) | 0.138 | 0.1 (0.0) | 15.9 (0.0) | 0.000 |
| Diabetes w/o complications | 165 (16.2) | 15706 (5.7) | 0.342 | 15.8 (1.8) | 4057.2 (1.8) | 0.000 |
| Dementia | 37 (3.6) | 2482 (0.9) | 0.016 | 0.9 (0.1) | 222.8 (0.1) | 0.000 |
| Immunocompromised | 14 (1.4) | 1375 (0.5) | 0.091 | 0.1 (0.0) | 19.9 (0.0) | 0.000 |
| RAAS inhibitors | 293 (28.8) | 30386 (11.0) | 0.458 | 49.1 (5.7) | 12637.9 (5.7) | 0.000 |
| Diuretics | 125 (12.3) | 9719 (3.5) | 0.330 | 4.6 (0.5) | 1189.4 (0.5) | 0.000 |
| COVID-related hospitalization | 34 (3.3) | 2590 (0.9) | 0.714 | 5.8 (0.7) | 874.1 (0.4) | 0.038 |
| All-cause 30-day hospitalization | 127 (12.5) | 14297 (5.2) | 0.260 | 46.2 (5.3) | 7475.4 (3.4) | 0.070 |
| COVID-related death | 38 (3.7) | 2898 (1.1) | 0.177 | 3.6 (0.4) | 752.1 (0.3) | 0.005 |

Table S7. Study 1: Matching covariates in Cohort B and Cohort C before [count (%)] and after matching [weighted count (%)] with standardized differences (d).

| Characteristics | Before matching | | | After matching | | |
|----------------------------------|-----------------|----------------|--------|-----------------|------------------|-------|
| | Cohort B | Cohort C | d | Cohort B | Cohort C | d |
| n | 95984 | 275804 | | 82323 | 268778 | |
| Age | | | | | | |
| [16,21) | 1389 (1.4) | 21127 (7.7) | -0.301 | 5212.5 (6.3) | 17018.5 (6.3) | 0.000 |
| [21,26) | 2142 (2.2) | 26298 (9.5) | -0.314 | 6606.9 (8.0) | 21571.1 (8.0) | 0.000 |
| [26,31) | 2869 (3.0) | 29134 (10.6) | -0.305 | 7427.3 (9.0) | 24249.7 (9.0) | 0.000 |
| [31,36) | 4034 (4.2) | 30974 (11.2) | -0.266 | 8125.6 (9.9) | 26529.4 (9.9) | 0.000 |
| [36,41) | 6002 (6.3) | 32123 (11.6) | -0.190 | 8834.9 (10.7) | 28845.1 (10.7) | 0.000 |
| [41,46) | 7706 (8.0) | 29678 (10.8) | -0.094 | 8629.7 (10.5) | 28175.3 (10.5) | 0.000 |
| [46,51) | 9166 (9.5) | 24825 (9.0) | 0.019 | 7799.4 (9.5) | 25464.6 (9.5) | 0.000 |
| [51,56) | 10689 (11.1) | 22057 (8.0) | 0.107 | 7444.0 (9.0) | 24304.0 (9.0) | 0.000 |
| [56,61) | 11457 (11.9) | 19062 (6.9) | 0.173 | 6816.8 (8.3) | 22256.2 (8.3) | 0.000 |
| [61,66) | 10697 (11.1) | 14962 (5.4) | 0.209 | 5542.7 (6.7) | 18096.3 (6.7) | 0.000 |
| [66,71) | 8561 (8.9) | 10422 (3.8) | 0.212 | 3882.8 (4.7) | 12677.2 (4.7) | 0.000 |
| [71,76) | 6715 (7.0) | 6473 (2.3) | 0.222 | 2478.4 (3.0) | 8091.6 (3.0) | 0.000 |
| [76,81) | 5466 (5.7) | 4138 (1.5) | 0.227 | 1590.7 (1.9) | 5193.3 (1.9) | 0.000 |
| [81,86) | 4924 (5.1) | 2820 (1.0) | 0.240 | 1194.9 (1.5) | 3901.1 (1.5) | 0.000 |
| [86,91) | 2984 (3.1) | 1274 (0.5) | 0.201 | 574.5 (0.7) | 1875.5 (0.7) | 0.000 |
| [91,96) | 1011 (1.1) | 362 (0.1) | 0.120 | 143.5 (0.2) | 468.5 (0.2) | 0.000 |
| [96,101) | 166 (0.2) | 75 (0.0) | 0.046 | 18.5 (0.0) | 60.5 (0.0) | 0.000 |
| [101,106) | 6 (0.0) | 0 (0.0) | 0.011 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| [106,111) | 0 (0.0) | 1 (0.0) | -0.003 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Sex | | | | | | |
| Male | 33604 (35.0) | 144549 (52.4) | -0.356 | 39525.9 (48.0) | 129049.1 (48.0) | 0.000 |
| Female | 62380 (65.0) | 131256 (47.6) | 0.356 | 42797.1 (52.0) | 139728.9 (52.0) | 0.000 |
| Vaccination status | | | | | | |
| 1/1, >90 days | 1 (0.0) | 1 (0.0) | 0.003 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/1, <14 days | 13 (0.0) | 38 (0.0) | 0.000 | 0.5 (0.0) | 1.5 (0.0) | 0.000 |
| 1/1, 14-90 days | 8 (0.0) | 43 (0.0) | -0.007 | 1.6 (0.0) | 5.4 (0.0) | 0.000 |
| Not vaccinated | 90719 (94.5) | 269393 (97.7) | -0.164 | 80697.9 (98.0) | 263472.1 (98.0) | 0.000 |
| 1/2, >90 days | 28 (0.0) | 16 (0.0) | 0.018 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/2, <14 days | 1724 (1.8) | 2667 (1.0) | 0.071 | 701.5 (0.9) | 2290.5 (0.9) | 0.000 |
| 1/2, 14-90 days | 2431 (2.5) | 2645 (1.0) | 0.120 | 745.6 (0.9) | 2434.4 (0.9) | 0.000 |
| 2/2, >90 days | 237 (0.2) | 201 (0.1) | 0.044 | 16.6 (0.0) | 54.4 (0.0) | 0.000 |
| 2/2, <14 days | 298 (0.3) | 205 (0.1) | 0.054 | 33.3 (0.0) | 108.7 (0.0) | 0.000 |
| 2/2, 14-90 days | 525 (0.5) | 596 (0.2) | 0.054 | 125.9 (0.2) | 411.1 (0.2) | 0.000 |
| Period | | | | | | |
| Up to January 9, 2021 | 55623 (58.0) | 163836 (59.4) | -0.030 | 49131.1 (59.7) | 160408.9 (59.7) | 0.000 |
| January 10 to July 15, 2021 | 39112 (40.7) | 106380 (38.6) | 0.045 | 31841.2 (38.7) | 103958.8 (38.7) | 0.000 |
| After July 15, 2021 | 1249 (1.3) | 5589 (2.0) | -0.057 | 1350.8 (1.6) | 4410.2 (1.6) | 0.000 |
| CCI | | | | | | |
| 0 | 55122 (57.4) | 230007 (83.4) | -0.593 | 66386.5 (80.6) | 216746.5 (80.6) | 0.000 |
| 1-2 | 31229 (32.5) | 40371 (14.6) | 0.431 | 14686.1 (17.8) | 47948.9 (17.8) | 0.000 |
| 3-4 | 7375 (7.7) | 4380 (1.6) | 0.293 | 1125.7 (1.4) | 3675.3 (1.4) | 0.000 |
| >=5 | 2258 (2.4) | 1047 (0.4) | 0.171 | 124.7 (0.2) | 407.3 (0.2) | 0.000 |
| Comorbidities | | | | | | |
| Atrial fibrillation/undulation | 5850 (6.1) | 4017 (1.5) | 0.245 | 1131.6 (1.4) | 3694.4 (1.4) | 0.000 |
| Autoimmune disease | 13295 (13.9) | 14282 (5.2) | 0.299 | 5214.2 (6.3) | 17023.8 (6.3) | 0.000 |
| Cancer | 7569 (7.9) | 7109 (2.6) | 0.240 | 2367.5 (2.9) | 7729.5 (2.9) | 0.000 |
| Congestive heart failure | 3907 (4.1) | 2149 (0.8) | 0.215 | 435.2 (0.5) | 1420.8 (0.5) | 0.000 |
| COPD | 12808 (13.3) | 17172 (6.2) | 0.241 | 5618.2 (6.8) | 18342.8 (6.8) | 0.000 |
| IHD or CVD | 12803 (13.3) | 8240 (3.0) | 0.385 | 3081.4 (3.7) | 10060.6 (3.7) | 0.000 |
| Renal disease | 2067 (2.2) | 1334 (0.5) | 0.147 | 152.4 (0.2) | 497.6 (0.2) | 0.000 |
| Diabetes + complications | 1611 (1.7) | 1131 (0.4) | 0.125 | 235.6 (0.3) | 769.4 (0.3) | 0.000 |
| Diabetes w/o complications | 15155 (15.8) | 15706 (5.7) | 0.330 | 5420.7 (6.6) | 17698.3 (6.6) | 0.000 |
| Dementia | 2356 (2.5) | 2482 (0.9) | 0.023 | 82.3(0.1) | 268.8 (0.1) | 0.000 |
| Immunocompromised | 1559 (1.6) | 1375 (0.5) | 0.110 | 265.0 (0.3) | 865.0 (0.3) | 0.000 |
| RAAS inhibitors | 30443 (31.7) | 30386 (11.0) | 0.522 | 11825.3 (14.4) | 38608.7 (14.4) | 0.000 |
| Diuretics | 14193 (14.8) | 9719 (3.5) | 0.398 | 3577.6 (4.3) | 11680.4 (4.3) | 0.000 |
| COVID-related hospitalization | 3128 (3.3) | 2590 (0.9) | 0.699 | 997.1 (1.21) | 2754.9 (1.0) | 0.018 |
| All-cause 30-day hospitalization | 11266 (11.7) | 14297 (5.2) | 0.237 | 5080.1 (6.2) | 15581.0 (5.8) | 0.014 |
| COVID-related death | 4261 (4.4) | 2898 (1.1) | 0.209 | 1191.7 (1.4) | 3295.2 (1.2) | 0.014 |

Table S8. Study 2: Matching covariates in Cohort Fluvoxamine and Cohort Paroxetine before [count (%)] and after matching [weighted count (%)] with standardized differences (d).

| Characteristics | Before matching | | | After matching | | |
|--------------------------------|-----------------|-------------|--------|----------------|---------------|-------|
| | Cohort Flu | Cohort Par | d | Cohort Flu | Cohort Par | d |
| n | 994 | 1796 | | 334 | 535 | |
| Age | | | | | | |
| [16,21) | 35 (3.5) | 5 (0.3) | 0.239 | 3.5 (1.0) | 5.5 (1.0) | 0.000 |
| [21,26) | 29 (2.9) | 20 (1.1) | 0.129 | 9.2 (2.8) | 14.8 (2.8) | 0.000 |
| [26,31) | 44 (4.4) | 38 (2.1) | 0.130 | 10.4 (3.1) | 16.6 (3.1) | 0.000 |
| [31,36) | 51 (5.1) | 63 (3.5) | 0.080 | 23.4 (7.0) | 37.6 (7.0) | 0.000 |
| [36,41) | 84 (8.5) | 121 (6.7) | 0.065 | 40.7 (12.2) | 65.3 (12.2) | 0.000 |
| [41,46) | 80 (8.0) | 160 (8.9) | -0.031 | 51.5 (15.4) | 82.5 (15.4) | 0.000 |
| [46,51) | 95 (9.6) | 197 (11.0) | -0.047 | 58.4 (17.5) | 93.6 (17.5) | 0.000 |
| [51,56) | 102 (10.3) | 202 (11.2) | -0.032 | 55.0 (16.5) | 88.0 (16.5) | 0.000 |
| [56,61) | 108 (10.9) | 210 (11.7) | -0.026 | 36.1 (10.8) | 57.9 (10.8) | 0.000 |
| [61,66) | 88 (8.9) | 215 (12.0) | -0.102 | 27.3 (8.2) | 43.7 (8.2) | 0.000 |
| [66,71) | 68 (6.8) | 160 (8.9) | -0.077 | 9.6 (2.9) | 15.4 (2.9) | 0.000 |
| [71,76) | 71 (7.1) | 153 (8.5) | -0.051 | 5.0 (1.5) | 8.0 (1.5) | 0.000 |
| [76,81) | 44 (4.4) | 107 (6.0) | -0.069 | 3.1 (0.9) | 4.9 (0.9) | 0.000 |
| [81,86) | 55 (5.5) | 93 (5.2) | 0.016 | 0.8 (0.2) | 1.2 (0.2) | 0.000 |
| [86,91) | 34 (3.4) | 40 (2.2) | 0.072 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| [91,96) | 5 (0.5) | 12 (0.7) | -0.022 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| [96,101) | 1 (0.1) | 0 (0.0) | 0.045 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| [101,106) | 0 (0.0) | 0 (0.0) | 0.000 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| [106,111) | 0 (0.0) | 0 (0.0) | 0.000 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Sex | | | | | | |
| Male | 431 (43.4) | 564 (31.4) | 0.249 | 111.8 (33.5) | 179.2 (33.5) | 0.000 |
| Female | 563 (56.6) | 1232 (68.6) | -0.249 | 222.2 (66.5) | 355.8 (66.5) | 0.000 |
| Vaccination status | | | | | | |
| 1/1, >90 days | 0 (0.0) | 0 (0.0) | 0.000 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/1, <14 days | 0 (0.0) | 0 (0.0) | 0.000 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/1, 14-90 days | 0 (0.0) | 0 (0.0) | 0.000 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Not vaccinated | 936 (94.2) | 1697 (94.5) | -0.014 | 331.7 (99.3) | 531.3 (99.3) | 0.000 |
| 1/2, >90 days | 0 (0.0) | 0 (0.0) | 0.000 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/2, <14 days | 23 (2.3) | 27 (1.5) | 0.059 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 1/2, 14-90 days | 27 (2.7) | 51 (2.8) | -0.008 | 1.5 (0.5) | 2.5 (0.5) | 0.000 |
| 2/2, >90 days | 1 (0.1) | 5 (0.3) | -0.041 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 2/2, <14 days | 0 (0.0) | 4 (0.2) | -0.067 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| 2/2, 14-90 days | 7 (0.7) | 12 (0.7) | 0.004 | 0.8 (0.2) | 1.2 (0.2) | 0.000 |
| Period | | | | | | |
| Up to January 9, 2021 | 574 (57.7) | 1061 (59.1) | -0.027 | 204.1 (61.1) | 326.9 (61.1) | 0.000 |
| January 10 to July 15, 2021 | 403 (40.5) | 716 (39.9) | 0.014 | 129.1 (38.7) | 206.9 (38.7) | 0.000 |
| After July 15, 2021 | 17 (1.7) | 19 (1.1) | 0.056 | 0.8 (0.2) | 1.2 (0.2) | 0.000 |
| CCI | | | | | | |
| 0 | 598 (60.2) | 981 (54.6) | 0.112 | 313.6 (93.9) | 502.4 (93.9) | 0.000 |
| 1-2 | 285 (28.7) | 648 (36.1) | -0.159 | 19.6 (5.9) | 31.4 (5.9) | 0.000 |
| 3-4 | 85 (8.6) | 132 (7.3) | 0.044 | 0.8 (0.2) | 1.2 (0.2) | 0.000 |
| >=5 | 26 (2.6) | 35 (1.9) | 0.045 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Comorbidities | | | | | | |
| Atrial fibrillation/undulation | 60 (6.0) | 84 (4.7) | 0.060 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Autoimmune disease | 110 (11.1) | 268 (14.9) | -0.115 | 4.2 (1.3) | 6.8 (1.3) | 0.000 |
| Cancer | 55 (5.5) | 128 (7.1) | -0.065 | 0.8 (0.2) | 1.2 (0.2) | 0.000 |
| Congestive heart failure | 30 (3.0) | 66 (3.7) | -0.037 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| COPD | 109 (11.0) | 269 (15.0) | -0.120 | 8.8 (2.6) | 14.2 (2.6) | 0.000 |
| IHD or CVD | 146 (14.7) | 241 (13.4) | 0.037 | 3.1 (0.9) | 4.9 (0.9) | 0.000 |
| Renal disease | 23 (2.3) | 31 (1.7) | 0.042 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Diabetes + complications | 18 (1.8) | 34 (1.9) | -0.006 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Diabetes w/o complications | 159 (16.0) | 315 (17.5) | -0.041 | 6.9 (2.1) | 11.1 (2.1) | 0.000 |
| Dementia | 37 (3.7) | 56 (3.1) | 0.033 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| Immunocompromised | 14 (1.4) | 23 (1.3) | 0.011 | 0.8 (0.2) | 1.2 (0.2) | 0.000 |
| RAAS inhibitors | 284 (28.6) | 644 (35.9) | -0.156 | 46.5 (13.9) | 74.5 (13.9) | 0.000 |
| Diuretics | 121 (12.2) | 281 (15.6) | -0.100 | 5.8 (1.7) | 9.2 (1.7) | 0.000 |
| F10-F19 | 27 (2.7) | 44 (2.4) | 0.017 | 0.0 (0.0) | 0.0 (0.0) | 0.000 |
| F20-F29 | 117 (11.8) | 112 (6.2) | 0.194 | 10.4 (3.1) | 16.6 (3.1) | 0.000 |
| F30-F39 | 434 (43.7) | 971 (54.1) | -0.209 | 128.0 (38.3) | 205.0 (38.3) | 0.000 |

| | | | | | | |
|---|------------|-------------|--------|---------------|---------------|--------|
| F40-F48 | 676 (68.0) | 1199 (66.8) | 0.027 | 266.4 (79.7) | 426.6 (79.7) | 0.000 |
| Any of F04-F09, F50-F59, F60-F69, F70-F79, F80-F89, F90-F98 | 218 (21.9) | 307 (17.1) | 0.122 | 25.4 (7.6) | 40.6 (7.6) | 0.000 |
| COVID-related hospitalization | 11 (1.1) | 17 (0.9) | 0.016 | 2.9 (0.9) | 0.9 (0.2) | 0.068 |
| All-cause 30-day hospitalization | 125 (12.6) | 206 (11.5) | 0.034 | 21.9 (6.5) | 28.8 (5.4) | 0.036 |
| COVID-related death | 37 (3.7) | 80 (4.5) | -0.037 | 1.5 (0.5) | 4.6 (0.9) | -0.020 |